Granules' business operations is divided into three areas; Core business, Emerging business & CRAMS. With a strong presence across all three vertical the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in `first line of defense' products such as Paracetamol Ibuprofen Metformin and Guaifenesin. Core business include Paracetamol, Ibuprofen, Guaifenesin and Metformin. The Company operates a healthcare division, Granules Consumer Healthcare (GCH). The Company, through an acquisition, has access to over 10 APIs, as well as intermediates in therapeutic categories, such as anti-histaminic, antihypertensive and anti-convulsants. The Company's PFI products include Compresso PAP 97 S, Compresso PAP 90 CPC and Paracetamol Caffeine Combo 77.4. The Company's FDs include Paracetamol/Acetaminophen, and Acetaminophen and Methocarbamol.

Granules India has a global presence across 60+ countries servicing over 250 customers. Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. The company has one of largest PFI and single site FD facilities in the world. It is also home to one of the World's largest Paracetamol API facilities.Granules India has eight manufacturing facilities out of which six are located in India and one in the US. It also has two operational manufacturing units located in India and China through its joint venture entities. The company has 250 customers present across 60 countries around the globe. The company's research center at Pragathi Nagar Hyderabad spread across an area of 15000 square feet epitomizes the company's focus on research and development.